GSK Update On FDA Review Of Promacta(R) (Eltrombopag)
Jun 30th 2008Drug InformationBlood
GlaxoSmithKline (NYSE: GSK) announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
